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The MC80R gene of molluscum contagiosum virus (MCV) type 1 encodes a major histocompatibility complex (MHC) class
I homolog that lacks several amino-acid residues critical for peptide binding by MHC molecules, contains an unusually long
N-terminal hydrophobic domain possibly derived by triplication of a signal peptide, and has a C-terminal transmembrane
domain with two glutamate residues. All of these features were present in the orthologous gene of MCV type 2. The MC80R
gene was expressed as two glycosylated polypeptides of Mr 47,000 and 42,000. Pulse-chase experiments indicated that the
larger polypeptide was a precursor of the shorter one and that the entire N-terminal domain was slowly removed, consistent
with its function as a long signal peptide. The protein was largely sequestered in the endoplasmic reticulum and Golgi
membranes, remained endoglycosidase-H sensitive, and was not detected on the cell surface. In addition, a genetically
modified form of the MC80R protein lacking the transmembrane and cytoplasmic domains was not secreted. The roles of the
MC80R protein domains were investigated by constructing chimera between the viral protein and the MHC class I protein
HLA-A2. Expression studies confirmed that the N- and C-terminal hydrophobic regions of the MC80R protein served as signal
and transmembrane domains, respectively. The central portion of the MC80R protein, corresponding to the a1–a3 extra-
cellular domains of HLA-A2, was largely responsible for sequestering the protein in the endoplasmic reticulum or Golgi
compartments. The MC80R protein, as well as HLA-A2 chimera with the central region of MC80R, formed stable intracellular
complexes with b2-microglobulin. Complex formation, however, was detected only by overexpression of the MC80R protein
or b2-microglobulin.
INTRODUCTION
Molluscum contagiosum virus (MCV) is a human pox-
virus with a worldwide distribution that causes small,
benign, skin tumors primarily in young children and sex-
ually active adults (Gottlieb and Myskowski, 1994). The
asymptomatic lesions may persist for several months or
longer but usually resolve spontaneously. In immunode-
ficient individuals, including AIDS patients, MCV causes
a severe and essentially untreatable opportunistic dis-
ease. A remarkable feature of MCV infection is the pro-
longed absence of an inflammatory response at the site
of replication, even in immunocompetent people (Heng
et al., 1989). In addition to the absence of T cells, natural
killer (NK) cells, and Langerhans cells, the infected ker-
atinocytes no longer display b2-microglobulin (b2m) re-
activity (Viac and Chardonnet, 1990). The inability to
propagate MCV in cell culture and the very limited rep-
lication in animal models with human skin grafts (Buller
et al., 1995; Fife et al., 1996) have prevented investiga-
tions of virus-host interactions. Analysis of the MCV
genome, however, revealed several candidate genes
that could contribute to protection against the immune
system (Senkevich et al., 1996, 1997). One such gene,
MC66L, encodes a homolog of glutathionine peroxidase
that is a selenoprotein and protects against peroxide-
mediated cell killing (Shisler et al., 1998). Another,
MC148R, encodes a chemokine homolog that inhibits
chemotaxis of monocytes, lymphocytes and neutrophils
(Krathwohl et al., 1997; Damon et al., 1998). A third,
MC80R, encodes a heretofore uncharacterized homolog
of a major histocompatibility complex (MHC) class I
protein.
MHC class I homologs are also encoded by human
(Beck and Barrell, 1988; Browne et al., 1990, 1992; Fah-
nestock et al., 1995) and mouse (Rawlinson et al., 1996;
Chapman and Bjorkman, 1998) cytomegaloviruses. Some
recent data suggest that these b herpesvirus proteins
protect infected cells against lysis by NK cells (Farrell et
al., 1997; Reyburn et al., 1997). Other data, however, have
not supported such a role for the human cytomegalovirus
protein (Leong et al., 1998), which has been shown to
bind to an immunoglobulin-like receptor that interacts
with cellular MHC class I proteins and is expressed
predominantly on monocytes, B lymphocytes, and a sub-
set of NK cells (Cosman et al., 1997). MCV and cytomega-
loviruses belong to different virus families, and their
MHC class I homologs share only limited sequence
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similarity suggesting that they were acquired indepen-
dently.
Here, we provide an initial description of the MC80R
gene product. The MCV protein was shown to be glyco-
sylated within the endoplasmic reticulum (ER) and se-
questered largely within the ER and Golgi compartments.
MC80 protein/b2m complexes formed within the ER but
were not detected on the cell surface, suggesting a
function different from that of the cytomegalovirus ho-
mologs.
RESULTS
Structural features of MC80R encoded by type I and
type II strains of MCV
The alignment of the MCV type I MC80R and the
human HLA-A2 MHC class I proteins (Fig. 1) is highly
significant since the probability of this degree of similar-
ity occurring by chance is less than 10220. Furthermore,
the domain organizations of MC80R and HLA-A2 are
similar with 27% identical amino acids in the a1–a3
domains, four conserved cysteines known to form disul-
fide bonds, and a single conserved N-glycosylation site
(Fig. 1). MC80R has approximately the same level of
similarity with all mammalian MHC class I molecules but
is less similar to nonmammalian MHC class I molecules
and all known MHC class I homologs including those
encoded by cytomegaloviruses (alignments not shown).
Despite the similarity between the MCV type I MC80R
protein and HLA-A2, there are a number of structural
differences that are likely to affect function. For example,
two of four tyrosines (namely Y159 and Y171) of HLA-A2
that interact with the peptide N termini (Madden, 1995)
are not conserved in MC80R (Fig. 1), making it unlikely
that the viral protein can bind and present peptides in the
same manner as MHC class I molecules. In this context,
the region of the MC80R molecule that aligns with the a2
domain of HLA-A2 contains two additional cysteines; a
potential intra- or intermolecular disulfide bond formed
by these cysteines could further disrupt the peptide-
binding groove. Another remarkable feature of MC80R is
the presence of an N-terminal hydrophobic domain that
is longer than any known cleavable signal peptide and
three times longer than that of HLA-A2 (Fig. 1). The
charged residues partition the N-terminal region into
three distinct hydrophobic segments, suggesting that
this domain may have evolved by triplication of a pro-
genitor signal peptide coding sequence. Although the
C-terminal hydrophobic domain of MC80R is colinear
with the transmembrane domain of HLA-A2, this region
of MC80R contains two negatively charged glutamate
residues not found in any other MHC class I molecule or
their homologs (Fig. 1).
Of the two predominant strains of MCV (Porter et al.,
1992), only the genome of type 1 had been sequenced
(Senkevich et al., 1996). We considered that the presence
FIG. 1. Alignment of the MC80R ORFs of MCV types 1 (gi1492023) and 2 (gi3600085) with the human lymphocyte antigen HLA-A2 (gi122138) MHC
class I protein. The alignment was constructed with the ALIGN program. Identities are designated by colons, conservative replacements by dots;
dashes represent gaps introduced to optimize alignment. The conserved N-glycosylation site, signal peptide and transmembrane domain of HLA-A2
are underlined. Conserved cysteines are indicated by the pound sign. The amino acids of HLA-A2 that participate in peptide binding are indicated
by asterisks, with those that are replaced in the viral protein indicated by exclamation points.
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of a highly conserved MC80R homolog in MCV type 2
isolates would support the importance of the unusual
structural features. Alternatively, if any of these features
were missing, the opposite would be suggested. The
MC80R homolog in MCV type 2 DNA was amplified by
PCR, using primers predicted from the flanking se-
quences of MCV type 1 DNA, and sequenced (GenBank
Accession No. AF085225). An alignment with the type 1
MC80R gene (Fig. 1) indicated a high degree of similarity
with 38 amino-acid substitutions. Moreover, the N-termi-
nal and the transmembrane domain each contained only
one conservative replacement, and there were no
changes in other residues highlighted above.
Expression of the MC80R ORF in mammalian cells:
Proteolytic processing and glycosylation
Since MCV does not replicate in cultured cells, vac-
cinia virus was used as a surrogate poxvirus for expres-
sion studies. Two different recombinant vaccinia viruses
were made; in one the MC80R ORF was placed under
the relatively weak P7.5 early/late promoter (Cochran et
al., 1985), and in the other, the ORF was placed under the
strong inducible bacteriophage T7 promoter (Ward et al.,
1995). To detect expression of the MC80R gene, we
raised antibodies to peptides comprising the C-terminal
part of the cytoplasmic domain and to the region colinear
with the a1 domain of HLA-A2. A mixture of these two
antibodies was used to immunoprecipitate [35S]methi-
onine-labeled proteins from lysates of recombinant virus-
infected cells. Two major bands of Mr 47,000 and 42,000
were detected by SDS–PAGE (Fig. 2), although in some
experiments there was an additional minor polypeptide
of intermediate mobility. Control experiments indicated
that these bands were not present when preimmune
serum was used or when the lysates were obtained from
cells infected with the vaccinia virus vector (not shown).
The two major forms of the protein were also labeled
when the MC80R ORF was transiently expressed in un-
infected cells (data not shown). The relative amounts of
the two polypeptides depended on the length of the
labeling period: with brief times the long form was pre-
dominant. Pulse-chase experiments supported a precur-
sor–product relationship (Fig. 2). The conversion of the
long form to the shorter one was relatively slow, and
traces of the former were still present after several hours
of chase. Cleavage evidently occurs in the endoplasmic
reticulum (ER) since similar results were obtained by
carrying out the pulse chase in the presence of brefeldin
A (data not shown), which prevents transport of proteins
to the Golgi compartment (Lippincott-Schwartz et al.,
1989; Yewdell and Bennink, 1989).
The mobilities of the long and short forms of the
MC80R protein were decreased by treatment with en-
doglycosidase-H (endo-H) or by synthesis in the pres-
ence of tunicamycin, indicating that both were N-glyco-
sylated (Fig. 3, in vivo). Moreover, in each case the
mobility shift was equivalent to a 2.5-kDa decrease, com-
patible with a single glycosylation site as predicted from
the sequence (Fig. 1). Therefore, the mobilities of the
short and long forms of the MC80R protein were not due
to differential glycosylation.
The latter results and the apparent precursor–product
relationship of the long and short forms of the MC80R
protein suggested that the size difference was due to
signal peptide cleavage. As mentioned earlier, the
MC80R gene appears to encode a triplicated signal
peptide of approximately 71 amino acids (Fig. 1). To
investigate whether the short form could arise by cleav-
age of all or part of this putative long signal peptide, we
constructed two templates for in vitro transcription/trans-
lation. One template contained the entire putative signal
peptide (Lsp), whereas the other contained an N-termi-
nally truncated version (Ssp) starting at codon 49 and
corresponding in size to the signal peptide of HLA-A2.
FIG. 3. SDS–PAGE analysis of glycosylated, unglycosylated, and
N-terminally truncated MC80R proteins. In vivo: BS-C-1 cells were
labeled with [35S]methionine for 30 min at 11 h after infection with
vSCMC80R in the absence (2) or presence (1) of 5 mg/ml of tunica-
mycin. Lysates were prepared and either treated (1) or untreated (2)
with endo-H and immunoprecipitated with anti-MC80 antibody. In vitro:
MC80R with the original long (Lsp) or a truncated short (Ssp) signal
peptide was synthesized in vitro and the products combined. All sam-
ples were treated with SDS and analyzed on the same polyacrylamide
gel. Bands detected with a PhosphorImager are shown with the posi-
tion of a 46-kDa marker indicated by an arrow.
FIG. 2. Precursor-product relationship between the two forms of
MC80R. BS-C-1 cells were infected with vSCMC80R, pulse-labeled with
[35S]methionine for 20 min at 11 h after infection, and then chased for
1.5 h. Lysates were prepared at both times, immunoprecipitated with
anti-MC80R antibodies, and analyzed by SDS–PAGE. Bands detected
with a PhosphorImager are shown with the position of a 46-kDa marker
indicated by an arrow.
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The cell-free translation products migrated as single
bands of expected sizes. In Fig. 3, the translation prod-
ucts of the two ORFs were mixed and analyzed on the
same gel as the unglycosylated in vivo products (Fig. 3).
The mobility of the larger unglycosylated MC80R protein
synthesized in vivo was similar to that of the polypeptide
synthesized in vitro from the full-length ORF, indicating
that it represents the uncleaved precursor. The mobility
of the smaller deglycosylated protein was faster than
that of the polypeptide synthesized in vitro from the
truncated template, suggesting that the former lost the
entire N-terminal hydrophobic domain. These data indi-
cated that the entire N-terminal hydrophobic domain
served as an unusually long signal peptide and that
glycosylation occurred prior to proteolytic processing.
Cell-free synthesis of the MC80R ORF in the
presence of microsomal membranes
Cell-free transcription/translation was carried in the
presence of canine microsomal membranes to confirm
that the full-length and shortened N-terminal hydropho-
bic domains could mediate translocation. Endoglycosi-
dase sensitivity after membrane solubilization was used
as evidence of translocation and intraluminal glycosyla-
tion. The full-length ORF gave rise to both long and short
endo-H-sensitive glycosylated products (Fig. 4) that cor-
responded in size to the in vivo products, whereas the
template with the short signal peptide gave rise to a
single endo-H-sensitive glycosylated product that was
identical in mobility to the shorter of the MC80R proteins
(Fig. 4). Taken together, these data showed that both the
full-length and truncated N-terminal hydrophobic do-
mains can function as signal peptides and that the
shorter form is cleaved more efficiently than the longer
one.
Association of the MC80R protein with b2m
The MC80R protein and b2m were co-expressed us-
ing the vaccinia virus/bacteriophage T7 transfection sys-
tem. A MC80R/b2m protein complex that was stable in
1% Triton X-100, 1% deoxycholate, 0.1% sodium dodecyl
sulfate lysis buffer was detected by co-immunoprecipi-
tation with polyclonal antibody to b2m or to antibody to
the MC80R protein (Fig. 5A). No complex was detected
when cells that expressed the two proteins separately
were mixed prior to lysis (data not shown). Both forms of
MC80R protein were complexed with b2m (Fig. 5A), con-
sistent with the association occurring within the ER prior
to signal peptide cleavage. Under these transfection con-
ditions, the same amount of MC80R protein was immu-
noprecipitated with polyclonal antibody to b2m or to the
MC80R protein, indicating efficient complex formation
(Fig. 5A). Similar complexes were obtained by cotrans-
FIG. 5. Association of MC80R protein with human b2m. (A) BS-C-1
cells were infected with vTF7–3 and cotransfected with plasmids con-
taining b2m and HLA-A2 or MC80R as indicated by plus or minus
signs. Labeling with [35S]methionine was from 12 to 13 h after infection.
Immunoprecipitation was carried out with the indicated antibodies (Ab):
anti-HLA-A2 (A2), anti-MC80R, or polyclonal or BBM.1 monoclonal an-
tibody to b2m. Immunoprecipitates were analyzed by SDS–PAGE, and
bands were detected with a PhosphorImager. The HLA-A2 protein
migrated as a single band slightly faster than the 46-kDa marker,
indicated by an arrow; the MC80R proteins migrated as two bands of
slower and faster mobility than HLA-A2; the more rapidly migrating
b2m band was cut off during preparation of the figure. (B) BS-C-1 cells
were infected with vac-b2m and coinfected with a virus expressing the
HLA-A2 ORF regulated by the P7.5 promoter (vac-A2) or the MC80R
ORF regulated by the P7.5 promoter (vSCMC80R) or the MC80R ORF
regulated by the inducible T7 promoter (vlacOIMC80R) in the presence
of 50 or 15 mM IPTG. Labeling was from 7 to 12 h after infection.
Immunoprecipitation was with the indicated antibodies (Ab): anti-
HLA-A2 (A2), anti-MC80R, or anti-b2m polyclonal antibody. SDS–PAGE
analysis was as in (A).
FIG. 4. In vitro processing of the MC80R protein in the presence of
microsomal membranes. In vitro transcription/translation of MC80R
with a long (Lsp) or a short (Ssp) signal peptide was carried out as
described in the legend to Fig. 3 except for the addition of canine
pancreatic microsomal membranes. Samples were treated (1) or un-
treated (2) with endo-H and analyzed by SDS–PAGE. Bands detected
with a PhosphorImager are shown with the position of a 46-kDa marker
indicated by an arrow.
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fecting plasmids encoding b2m and HLA-A2 (Fig. 5A).
One difference between the complex of b2m with
HLA-A2 and with MC80R was that only the former bound
efficiently to the b2m monoclonal antibodies BBM.1 (Fig.
5A) and L368 (not shown), suggesting that the b2m
epitope was covered or altered by binding to the MC80R
protein.
When b2m, MC80R, and HLA-A2 were expressed by
recombinant vaccinia viruses under the relatively weak
early/late P7.5 promoter, complex formation was de-
tected between b2m and HLA-A2 but not between b2m
and MC80R (Fig. 5B). Moreover, when the MC80R ORF
was expressed under the inducible T7 promoter, high
levels of synthesis induced by 50 mm IPTG were required
to detect the complex (Fig. 5B). Several experiments
were carried out in which HLA-A2 and MC80R were
co-expressed along with b2m. A reduction in HLA-A2/
b2m complex formation, as determined by co-immuno-
precipitation, was only found with a relatively high level
of MC80R protein (data not shown). Whether the require-
ment for high amounts of MC80R protein reflects ineffi-
cient folding or intracellular trafficking of the MC80R
protein, interference by a cellular protein, or a low affinity
of the MC80R protein for b2m remains to be determined.
Intracellular localization of the MC80R protein
The intracellular location of the MC80R protein was
determined by indirect immunofluorescence microscopy.
After fixation and permeabilization, intense perinuclear
Golgi network and ER staining patterns were noted (Fig.
6). The MC80R protein was not detected on the cell
surface when fixed but unpermeabilized cells were
stained (not shown). Similarly, we could not detect cell
surface MC80R protein either by FACS analysis or by
biotinylation of unpermeabilized cells (data not shown).
Furthermore, deletion of the putative C-terminal trans-
membrane segment did not result in the secretion of the
truncated MC80R protein, suggesting that the central
portion of the MC80R protein prevented cell surface
expression.
Additional experiments were performed to determine
whether MC80R/b2m complexes could be presented on
the cell surface. BS-C-1 cells, co-infected with vaccinia
viruses expressing b2m and MC80R for 12 h, were
stained with polyclonal anti-b2m antibody. FACS analysis
did not reveal staining above background, whereas HLA-
A2/b2m complexes were readily detected (Fig. 7). More-
over, the amount of surface HLA-A2/b2m complex was
unchanged when MC80R was co-expressed (data not
shown).
Roles of the domains comprising the MC80R protein
To assess the contributions of the individual domains
of MC80R to intracellular trafficking and b2m binding, we
made MC80R/HLA-A2 chimera. One set of chimera con-
tained the signal peptide and central region of either
HLA-A2 or MC80R but lacked C-terminal transmembrane
sequences (Fig. 8A). The chimera were expressed using
the vaccinia virus/T7 transfection system. Each of the
hybrid proteins formed a complex with b2m, as shown by
coprecipitation of intracellular protein with polyclonal
antibody to b2m (Fig. 8B). In addition, the mobility shift
FIG. 7. FACS analysis of cells expressing MC80R and b2m. BS-C-1
cells were co-infected with vac-b2m and vGW3 encoding b-galactosi-
dase (b2m 1 b-gal, shaded) in the presence of 50 mM IPTG or vac-b2m
and vlacOIMC80R (b2m 1 MC80R, unshaded) in the presence of 50
mM IPTG or vac-b2m and vac-A2 (b2m 1HLA-A2, unshaded). After
12 h, the infected cells were stained with polyclonal anti-b2m antibody
conjugated to fluorescein and analysed on a FACScan. The horizontal
and vertical axes represent fluorescence intensity and cell number,
respectively.
FIG. 6. Localization of MC80R by confocal microscopy. BS-C-1 cells
on coverslips were infected with 10 PFU/cell of vTF7–3 and transfected
with pVote-MC80R. At 18 h after infection, the cells were fixed, perme-
abilized, and incubated with polyclonal antibodies to MC80R and
stained with rhodamine-conjugated swine anti-rabbit antibody.
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after treatment with endo-H indicated that the proteins
were all glycosylated. The proteins with the central re-
gion of HLA-A2 and the signal peptide of either HLA-A2
(chi-2) or MC80R (chi-10) were secreted into the medium
(Fig. 8B). However, the protein with the central region of
MC80R and the signal peptide of HLA-A2 (chi-3; Fig. 8B)
or MC80R (not shown) were not secreted. These data
confirmed the ability of the long N-terminal hydrophobic
sequence of MC80R to serve as a cleavable signal pep-
tide and the role of the central region in preventing
surface expression.
A second set of chimera that retained the transmem-
brane regions of HLA-A2 or MC80R were made (Fig. 9A)
and transiently expressed using the vaccinia T7 system
(Fig. 9B). All of the chimeric proteins were glycosylated,
and the degree of endo-H sensitivity, indicated by an
increase in mobility on SDS–PAGE, correlated with the
origin of the central region; those derived from MC80R
(MC80R, chi-4, chi-8, chi-11) were completely endo-H
sensitive, whereas those with the central region of
HLA-A2 (HLA-A2, chi-5, chi-7) were predominantly resis-
tant. However, the hybrid containing the MC80R cyto-
plasmic and transmembrane domains (chi-1) was as
endo-H sensitive as the MC80R protein (Fig. 9B).
The abilities of the MC80R N-terminal and transmem-
brane domains to serve as signal and anchor se-
quences, respectively, were also analyzed by cell sur-
face staining with antibody to b2m and FACS analysis.
Positive cell surface staining was detected when plas-
mids that encode b2m and the central region of HLA-A2
(HLA-A2, chi-5, chi-7, or chi-1) were cotransfected (Fig.
10), although the MC80R signal peptide or transmem-
brane domain were less efficient than the corresponding
region of HLA-A2. By contrast, no cell surface staining
was detected by transfection of plasmids encoding chi-
mera that contain the central region of MC80R, regard-
less of whether monoclonal or polyclonal antibody to
b2m was used (data not shown).
DISCUSSION
The present study provides an initial characterization
of the protein encoded by the MC80R ORF of MCV type
1 as well as the DNA sequence of the corresponding
ORF from MCV type 2. We confirmed several predictions
based on the sequence of MC80R and its homology with
MHC class I molecules, namely that it is a type 1 trans-
membrane protein and is capable of binding b2m. Al-
though we did not look for peptide loading of MC80R
protein, we doubt that this occurs because of the ab-
sence of conserved amino acids required for MHC class
I molecules to perform this function. This is in contrast to
UL18, the MHC class I homolog of human cytomegalovi-
rus, which has been shown to bind peptide (Fahnestock
et al., 1995). In this regard MC80R may be more similar to
m144, the MHC class I homolog of mouse cytomegalo-
virus, which has a deletion in the region corresponding
to the a2 domain and has been reported not to bind
peptide (Chapman and Bjorkman, 1998).
The length of the N-terminal domain is an unusual
feature of the MC80R protein of both type 1 and type 2
MCV. The pattern of positively charged amino acids sug-
gested that it evolved by triplication of a primordial signal
peptide. We confirmed by in vivo and in vitro experiments
that the entire segment functioned as a cleavable signal
peptide but that processing was slow and inefficient. In
addition, the N-terminal segment of MC80R could effec-
tively substitute for the signal peptide of HLA-A2. The
more rapid cleavage of a truncated form of the signal
peptide suggested that the delay was a consequence of
its unusual size or structure rather than the sequence
around the cleavage site. The function of this domain
may be to prolong the intracellular trafficking time of the
MC80R protein. We could not find a signal peptide with
this unusual structure in any described eukaryotic or
other viral protein.
The C-terminal domain of MC80R differs from trans-
FIG. 8. Secretion of truncated HLA-A2/MC80R chimeric proteins. (A)
Schematic representation of HLA-A2/MC80R chimeric proteins (chi-2,
chi-10, chi-3). HLA-A2 and MC80R domains are represented in black
and gray, respectively. The N-terminal signal peptides are indicated by
the thick bars and the luminal domains by thin bars. A few amino acids
derived from the MC80R transmembrane sequence are present in all
constructs. The numbers (1, 76, and 345) indicate the amino-acid
segments of MC80R used to make chimera with HLA-A2. (B) BS-C-1
cells were infected with vTF7–3 and cotransfected with plasmids con-
taining b2m and HLA-A2/MC80R chimera. The cells were labeled from
11 to 12 h after infection and chased for 10 h. The culture medium was
collected (secreted), and the cells were washed and lysed (intracellu-
lar). The lysates were divided into two portions and one was treated
with endo-H (1) and one was untreated (2). Immunoprecipitations
were carried out with anti-b2m polyclonal antibody. Bands were de-
tected using a PhosphorImager.
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membrane domain of any MHC class I molecule or
cellular or viral homolog in that this hydrophobic seg-
ment contains two negatively charged glutamate resi-
dues. Both glutamates are conserved in MCV types I and
II. Charged or polar residues, though not common in
transmembrane domains, were described in several in-
tegral membrane proteins where they have been asso-
ciated with specific functions (Manolios et al., 1990; Cos-
son et al., 1991; Chen et al., 1997; Fiedler and Rothman,
1997). For example, glutamate residues in the trans-
membrane domain of the oncogenic mutated form of
p185c-new receptor tyrosine kinase are involved in dimer
formation and are indispensable for the transforming
activity of the protein (Chen et al., 1997). Domain-swap-
ping studies demonstrated that the C-terminal hydropho-
bic region of MC80R could substitute for the anchor
sequence of HLA-A2, although transport to the cell sur-
face was reduced and occurred without terminal glyco-
sylation.
We considered that the MC80R protein could contrib-
ute to the observed loss of b2m reactivity on the surface
of MCV-infected keratinocytes in skin lesions (Viac and
Chardonnet, 1990). In this context, we demonstrated
MC80R/b2m complexes. When both proteins were ex-
pressed at high levels, using the vaccinia virus/T7 tran-
sient expression system, similar amounts of MC80R pro-
tein were immunoprecipitated with antibody to MC80R or
b2m. However, the complex was undetectable at lower
expression levels. In addition, HLA-A2 appeared to suc-
cessfully compete with MC80R protein for binding to
b2m unless very high amounts of the viral protein were
made. Moreover, cell surface expression of HLA-A2 was
unchanged by co-expression of MC80R. It is possible,
however, that our in vitro conditions do not mimic the
situation that occurs in MCV-infected keratinocytes with
regard to the timing, level, and duration of viral gene
expression as well as the synthesis of other MCV pro-
teins. Alternatively, the MC80R protein may have a low
affinity for b2m precluding its efficient competition with
MHC class I heavy chains. One speculative idea is that
MHC class I heavy chains are destroyed by other viral
mechanisms and MC80R/b2m complex formation serves
as a gauge for measuring free b2m before the level of
surface MHC class I molecules falls below the threshold
for prevention of NK cell activity. The possibility that the
MC80R protein interferes with other steps in the presen-
tation of peptides by MHC class I molecules, e.g., the
TAP transporter, is under investigation.
MHC class I molecules on the surface of cells inhibit
NK cell activation and cell lysis (Lo´pez-Botet et al., 1996).
Thus by downregulating MHC class I, a virus infection
can trigger NK cell activation (Brutkiewicz and Welsh,
1995). Because of its homology, we previously suggested
that the MC80R protein might mimic the NK-inhibitory
function of MHC class I molecules (Senkevich et al.,
1996). Indeed, initial evidence for such a role has been
obtained for MHC class I homologs encoded by murine
(Farrell et al., 1997) and human (Reyburn et al., 1997)
cytomegaloviruses. Such an interaction for the human
cytomegalovirus homolog, however, has been ques-
FIG. 9. Glycosylation and endo-H sensitivity of MC80R/HLA-A2 chimeric proteins. (A) Schematic representation as in Fig. 8A except that the
C-terminal transmembrane (thick bars) and cytoplasmic domains (thin bars) are shown. The amino acids corresponding to MC80R are numbered.
Endo-H resistance determined in (B), and cell surface expression analyzed by FACS are indicated by plus or minus signs. (B) Infection, transfection,
metabolic labeling, endo-H treatment, immunoprecipitation, and SDS–PAGE were carried out as described in the legend to Fig. 8B. The position of
a 46-kDa marker is shown.
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tioned (Leong et al., 1998). Since surface expression is a
precondition for interaction with NK cells, we investi-
gated the location of the MC80R protein alone or in
complex with b2m. Despite the functionality of the
MC80R signal peptide and C-terminal transmembrane
domain, the MC80R protein was not detected on the cell
surface and appeared to accumulate in the ER and Golgi
compartments. We found that (i) MC80R and all hybrid
proteins containing the central region of MC80R are
endo-H sensitive even after a long chase, indicating that
they do not acquire terminal glycosylation in medial/
trans Golgi compartments; (ii) the MC80R/b2m complex
was not detected on the cell surface in contrast to the
HLA-A2/b2m complex when similar amounts of each
complex were present in the total cell extract; (iii) hybrid
proteins containing the central region of MC80R or their
complexes with b2m were not detected on the cell sur-
face; (iv) fusion of the transmembrane and cytoplasmic
domains of MC80R to the central region of HLA-A2 in-
hibited terminal glycosylation and resulted in decreased
transport of HLA-A2 to the cell surface; and (v) deletion of
the transmembrane domain of MC80R or hybrid proteins
containing the body of MC80R did not result in secretion.
Thus the structure of the MC80R protein as well as the
kinetics of b2m complex formation and intracellular traf-
ficking is distinct from those of MHC class I proteins and
their homologs encoded by b-herpesviruses. These data
do not support a direct role for the MC80R protein in
inhibition of NK cell activation. However, it remains pos-
sible that cell surface expression does occur during a
natural MCV infection either because other MCV or cel-
lular proteins are needed for proper folding and trans-
FIG. 10. Cell surface expression of b2m. BS-C-1 cells were infected with vTF7–3 and cotransfected with plasmids encoding b2m and
b-galactosidase (b-gal) or HLA-A2 or a chimeric MC80R/HLA-A2 protein (Fig. 9A). At 18 h after infection, the cells were stained with monoclonal
anti-b2 antibody (BBM-1) followed by secondary antibodies conjugated to R-phycoerythrin, and analyzed on a FACScan. The unshaded portions
correspond to the control b2m plus b-gal and the shaded portions to b2m plus HLA or a chimeric protein. The horizontal and vertical axes represent
fluorescence intensity and cell number, respectively.
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port. In this regard, it would be interesting to look for cell
surface expression of MC80R in sections of MCV le-
sions.
MATERIALS AND METHODS
Sequence of the MC80R gene of MCV type 2
MCV type II genomic DNA was provided by C. H.
Thompson (University of Sydney, Australia) and used as
a template to amplify the MC80R gene with primers
59-GTGGTGGAGAAGAAGGTGGAGGACATTG and 59-
GATCACCAGCGTCTTGAGGTCCATTTATC, based on the
MCV type I sequence. The same primers and additional
ones were used to sequence the gene with the ABI 373A
automated sequencer.
Expression and transfer vectors
A copy of the MC80R ORF was amplified by the poly-
merase chain reaction (PCR; expand long template PCR
system, Boehringer Mannheim) using the EcoRI D frag-
ment of MCV type I DNA (Bugert and Darai, 1991) as the
template and the oligonucleotide primers: 59-CGCGGCG-
GTCATGACGGGCACGCTCATACT (BspHI site under-
lined; initiation codon in bold) and 59-CGCGGATC-
CGCTCGCCGCCTAGAAG (BamHI site underlined). The
PCR product was purified with Wizard PCR Preps kit
(Promega), digested with BspHI and BamHI, and inserted
into plasmid pVote I (Ward et al., 1995), generating pVote-
MC80R. To generate pSC-MC80R, pVote-MC80R was
digested with BamHI and the overhanging oligonucleo-
tides were filled in with bacteriophage T4 DNA polymer-
ase; the blunt-ended DNA was cleaved with BspHI and
the insert was cloned between NcoI and KpnI (39 over-
hang removed by T4 DNA polymerase) of pSC11
(Chakrabarti et al., 1985) modified to contain a multiple
cloning site (Bacik et al., 1994). The primers 59-GCACG-
GCCATGGGCCTGCGCGCTATTC (NcoI site underlined;
initiation codon in bold) and 59-CTCTGGGATCCTCTA-
GAGCTAAGCAACGCGGGCACTC (BamHI site under-
lined) were used to generate N- or C-terminal truncation
mutants of MC80R, respectively.
Recombinant PCR was used to make chimeric MC80/
HLA-A2 genes. Briefly, regions of MC80R, HLA-A2 or
chimeras were amplified, and the products were purified
as described above. Two corresponding PCR products
were mixed together and used as template/primer in
recombinant PCR reaction without any additional prim-
ers for 4 cycles, then external primers were added
and the process was continued for 25 cycles. The
primers, 59-CGTGTGCGCGTGCGCGTGCGCGAGCAGTG;
59-CTGAGTTACGTGGCCGCGGTCGTGTAC; 59-GC-
GCCGTTTCCCCTCCTCCCAG; 59-GAGCCGTCTTC-
CCAGCCCACCGTCGCGACGAGTGCCCGCGTTG); and
59-ACTGGAGCTGTGGTCGCTGCTGTGATCCTGCGCGAG-
CGGCGCC, were used to amplify different regions of
MC80R for recombinant PCR (sequences complemen-
tary to HLA-A2 are in italics). The primers 59-CGCCGAC-
CATGGCCGTCATGGCGCCCCGAAC (NcoI site under-
lined; initiation codon in bold) 59 GGCAGGATCCTCA-
CACTTTACAAGCTGTGAGAGA (BamHI site underlined)
and a pSC11 plasmid containing HLA-A2.1 gene (O’Neil
et al., 1993) were used to amplify the HLA-A2 gene. The
primers: 59 GTACACGACCGCGGCCACGTAACTCAGG-
GAGTGAGAGCCCGCCCAGGT, 59-CACTGCTCGCG-
CACGCGCACGCGCACACGATGAGGTATTTCTACAC-
CTCC; 59-CAACGCGGGCACTCGTCGCGACGGTGG-
GCTGGGAAGACGGCTC; and 59-CAGCAGCGACCA-
CAGCTCCAGTGA were used to amplify different regions
of HLA-A2 (sequences complementary to HLA-A2 are in
italics; MC80R sequences are in regular font). Because
the same primer that was used to make the C-terminal
truncation mutant of MC80R was used to create chi-2
from chi-1, chi-2 contained a small region from the trans-
membrane domain of MC80R. The HLA-A2 gene, trunca-
tion mutants of MC80R, and chimeric genes were cloned
between NcoI and BamHI sites of pVote I. The plasmid
containing human b2m gene under T7 promoter (Shields
et al., 1998) was provided by R. K. Ribaudo, NCI, NIH.
Cells and viruses
BS-C-1 cells (ATTC CCL6) were grown in Eagle’s min-
imum essential medium (EMEM; Quality Biologicals),
supplemented with 10% fetal bovine serum (FBS). All
recombinant vaccinia viruses were derived from WR
strain (ATTC Vr119). Recombinant vaccinia virus express-
ing the MC80R open reading frame under the P7.5 pro-
moter (vSCMC80R) was obtained by homologous recom-
bination between the genome of the wild-type virus and
pSC11-MC80R and was selected and propagated by
standard procedures (Earl and Moss, 1991). Vaccinia
viruses with HLA-A2.1 (vac-A2) and human b2m (vac-
b2m) genes expressed under the P7.5 promoter were
prepared similarly and provided by J. Bennink and J. W.
Yewdell (O’Neil et al., 1993). Recombinant vaccinia virus
expressing MC80R under the inducible T7 promoter
(vlacOIMC80R) was obtained by homologous recombi-
nation of vT7lacOI (Alexander et al., 1992; Ward et al.,
1995) with pVote-MC80R and was selected in the pres-
ence of mycophenolic acid and propagated as described
(Earl and Moss, 1991). vGW3 is a vaccinia virus express-
ing b-galactosidase under the inducible T7 promoter
(Ward et al., 1995).
Transfection of vaccinia virus-infected cells with
recombinant plasmids for transient expression
BS-C-1 cells were infected with 10 plaque forming
units (PFU) of vTF7–3, a recombinant vaccinia virus ex-
pressing the T7 polymerase gene (Fuerst et al., 1986),
and transfected 1 h later with plasmids mixed with lipo-
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fectAMINE according to the manufacturer’s protocol (Life
Technologies).
Antibodies
Polyclonal antibodies were raised in rabbits to a 22-
amino-acid peptide HRQSGSVLPSPEWAPSVYFHDE from
the a1 domain or to a 17-amino-acid peptide CSMPN-
LLPQALRERAGF from the C-terminal part of the cytoplas-
mic tail of MC80R. Other antibodies used were: mono-
clonal W6/32 (ATCC HB 95) against HLA-A, -B, -C; mono-
clonal BBM.1 (ATCC HB 28), L368 (ATCC HB 149), and
polyclonal against human b2m, unlabeled, or conjugated
to fluorescein isothiocyanate (DAKO, Carpinteria, CA).
Immunoprecipitation and SDS–PAGE analysis of
metabolically labeled polypeptides and endo-H
treatment
BS-C-1 cells were infected with 10 PFU/cell of a single
virus or with 10 PFU/cell each of multiple viruses in the
presence or absence of isopropyl-b-D-thiogalactoside
(IPTG) or were infected and transfected as described
above. At indicated times after infection, the cells were
incubated with methionine-free medium for 30 min and
pulse labeled for indicated time with 100 mCi/ml of
[35S]methionine. For chase experiments, the cells were
washed twice with regular medium, and the incubation
was continued in regular medium. At the end of labeling
or chase periods, the cells were washed twice with
phosphate buffered saline (PBS), disrupted with 1% Tri-
ton X100, 1% deoxycholate in PBS, and incubated with
protein A beads (Pierce) that had been complexed with
antibodies. For the analysis of secreted proteins, the
culture medium was used instead of cell extracts. Pro-
tein A beads were washed extensively and the bound
proteins analyzed by electrophoresis in a SDS 10–18%
polyacrylamide gradient gel (OWL Separation Systems,
MA). For endo-H (New England Biolabs, Beverly, MA)
treatment, samples were denatured in 0.5% SDS, 1%
b-mercaptoethanol at 100°C for 10 min and incubated in
50 mM sodium citrate pH 5.5 for 1 h at 37°C with or
without enzyme. Gels were fixed, dried, and analyzed
using a PhosphorImager (Storm 860, Molecular Dynam-
ics).
In vitro translation
The complete or truncated MC80R open reading frame
(ORF) in the pVote 1 vector was transcribed and trans-
lated in a coupled system (TNT T7 Quick Coupled Tran-
scription/Translation System, Promega) with or without
added canine pancreatic microsomal membranes, ac-
cording to the Promega technical manual. Membrane-
associated proteins were separated from nonmembrane
proteins by centrifugation in an Eppendorf centrifuge at
14,000 rpm for 10 min and washed three times in PBS.
Pellets were analysed by SDS–PAGE with or without
endo-H treatment.
Indirect immunofluorescence and confocal
microscopy
BS-C-1 cells on coverslips were infected with 10 PFU/
cell of vTF7–3 and transfected with pVote-MC80R as
described above. At 18 h after infection, the cells were
fixed with 3% paraformaldehyde in PBS, permeabilized in
0.05% saponin (Calbiochem, San Diego, CA) in PBS,
incubated with the mixture (1:1) of polyclonal antibodies
to MC80R described above, and stained with rhodamine-
conjugated swine anti-rabbit antibody (DAKO). Samples
were analyzed with a Zeiss LSM 410 confocal micro-
scope.
Flow cytometry analysis
Monolayers of BS-C-1 cells that were infected or in-
fected and transfected, as described above, were
washed in PBS containing 0.1% bovine serum albumin,
collected by pipetting, incubated with primary antibodies,
followed by secondary antibodies conjugated to fluores-
cein isothiocyanate or R-phycoerythrin. Cell surface flu-
orescence was analysed with a Becton Dickinson FAC-
Scan.
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